Journal of Clinical Endocrinology & Metabolism, Vol 74, 192-197, Copyright © 1992 by Endocrine Society

ARTICLES

Effect of insulin resistance and hyperglycemia on proinsulin release in a primate model of diabetes mellitus

SE Kahn, DK McCulloch, MW Schwartz, JP Palmer and D Porte Jr
Department of Medicine, University of Washington, Seattle.

An elevated plasma proinsulin (PI) to immunoreactive insulin (IRI) ratio occurs in relatives of patients with insulin-dependent diabetes mellitus and in subjects with non-insulin-dependent diabetes mellitus. To determine whether this alteration is the result of B-cell dysfunction and/or insulin resistance, we infused nicotinic acid for 3 weeks to produce insulin resistance in five adolescent male baboons before and after the administration of streptozocin (200 mg/kg). We measured basal PI and IRI levels and the acute incremental PI (APIR) and IRI (AIRIR) responses to iv arginine. The quantity of IRI comprised of PI was calculated in the basal state (PI/IRI) and following arginine injection (APIR/AIRIR). Streptozocin administration did not change the fasting plasma glucose (FPG) compared to that in the normal animals (4.7 +/- 0.3 vs. 4.3 +/- 0.2 mM) but raised the PI/IRI (16.4 +/- 3.4 vs. 5.9 +/- 1.7%) and APIR/AIRIR (7.1 +/- 1.0 vs. 2.8 +/- 1.0%) due to a concurrent reduction in IRI and increase in PI concentrations. The induction of experimental insulin resistance with nicotinic acid in the normal animals had no effect on the FPG (4.4 +/- 0.2 mM) but in the streptozocin treated animals, fasting hyperglycemia (8.3 +/- 1.7 mM) developed. Neither the basal PI/IRI (10.2 +/- 2.2%) or the APIR/AIRIR (2.3 +/- 0.6%) increased in the insulin-resistant streptozocin animals thus being no different to that of normal control animals before or during experimental insulin resistance. We conclude that disproportionate proinsulinemia is a manifestation of B-cell damage from streptozocin which is not exacerbated by insulin resistance or hyperglycemia.

This article has been cited by other articles:

				S. A. Smith, L. E. Porter, N. Biswas, and M. I. Freed Rosiglitazone, But Not Glyburide, Reduces Circulating Proinsulin and the Proinsulin:Insulin Ratio in Type 2 Diabetes J. Clin. Endocrinol. Metab., December 1, 2004; 89(12): 6048 - 6053. [Abstract] [Full Text] [PDF]

				A. Fritsche, A. Madaus, N. Stefan, O. Tschritter, E. Maerker, A. Teigeler, H. Haring, and M. Stumvoll Relationships Among Age, Proinsulin Conversion, and {beta}-Cell Function in Nondiabetic Humans Diabetes, February 1, 2002; 51(90001): S234 - 239. [Abstract] [Full Text] [PDF]

				S. E. Kahn The Importance of {beta}-Cell Failure in the Development and Progression of Type 2 Diabetes J. Clin. Endocrinol. Metab., September 1, 2001; 86(9): 4047 - 4058. [Full Text] [PDF]

				M. Stumvoll, A. Fritsche, N. Stefan, E. Hardt, and H. Häring Evidence against a Rate-Limiting Role of Proinsulin Processing for Maximal Insulin Secretion in Subjects with Impaired Glucose Tolerance and {beta}-Cell Dysfunction J. Clin. Endocrinol. Metab., March 1, 2001; 86(3): 1235 - 1239. [Abstract] [Full Text]

				M. E. Røder, R. S. Schwartz, R. L. Prigeon, and S. E. Kahn Reduced Pancreatic B Cell Compensation to the Insulin Resistance of Aging: Impact on Proinsulin and Insulin Levels J. Clin. Endocrinol. Metab., June 1, 2000; 85(6): 2275 - 2280. [Abstract] [Full Text]

				R. L. Prigeon, S. E. Kahn, and D. Porte Jr. Effect of Troglitazone on B Cell Function, Insulin Sensitivity, and Glycemic Control in Subjects with Type 2 Diabetes Mellitus J. Clin. Endocrinol. Metab., March 1, 1998; 83(3): 819 - 823. [Abstract] [Full Text]

				M. E. Røder, D. Porte Jr., R. S. Schwartz, and S. E. Kahn Disproportionately Elevated Proinsulin Levels Reflect the Degree of Impaired B Cell Secretory Capacity in Patients with Noninsulin-Dependent Diabetes Mellitus J. Clin. Endocrinol. Metab., February 1, 1998; 83(2): 604 - 608. [Abstract] [Full Text]